Gastric cancer and Helicobacter pylori infection

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 3, 2006, Pages 51-65

  Konturek, P C ^a   Konturek, S J ^b   Brzozowski, T ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

COX 2; Gastric cancer; Gastrin; Helicobacter pylori; Mongolian gerbils; Survivin

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GASTRIN; GROWTH FACTOR; IMMUNOGLOBULIN G; PROSTAGLANDIN E2; PROTEIN BCL 2; SURVIVIN; VASCULOTROPIN; VIRULENCE FACTOR;

ATROPHIC GASTRITIS; BACTERIAL INFECTION; BARRETT ESOPHAGUS; CANCER RISK; CARCINOGENESIS; CELL TRANSFORMATION; CHRONIC GASTRITIS; CLINICAL TRIAL; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; NONHUMAN; PREVALENCE; PROTEIN EXPRESSION; REVIEW; STOMACH CANCER;

ANIMALS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS; VIRULENCE FACTORS;

EID: 33750366466     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. nd English Edition. Gastric Cancer 1998; 1: 10-24.
2. Lauren P. The two histological maint types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
3. Tatematsu M, Ichnose M, Miki K. Gastric and intestinal phenotypic expression of human stomach cancers as revealed by pepsinogen immunohistochemistry and mucin histochemistry. Acta Pathol Jpn 1990; 40: 494-504.
4. Tahara E. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993; 119: 265-272.
5. Yamagiwa K. Causative factors of gastric cancer. In Gastric Carcinogenesis, K Yamagiwa (ed). Tokyo, Keisei-sha, 1981, pp. 213-250.
6. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362.
7. Kaneko S, Yoshimura T. Time trend analysis of gastric cancer incidence in Japan by histological types, 1975-1989. Br J Cancer 2001; 84: 400-405
8. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 suppl 8: S4-S66.
9. Parkin DM. International variation. Oncogene 2004; 23: 6329-6340.
10. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289.
11. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002; 11: 235-256.
12. Munoz N, Correa P, Cuello C, Duque E. Histologic types of gastric carcinoma in high - and now-risk areas. Int J Cancer1968; 3: 809-818.
13. Blaser MJ. An endangered specoes in the stomach. Sci Am 2005; 292: 38-45.
14. Sharris AW, Gummett PA, Walker MM, Misiewicz JJ, Baron JH. Relation between gastric acid output, Helicobacter pylori and gastric metaplasia in the duodenal bulb. Gut 1996; 39: 13-20.
15. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003; 98: 1462-1470
16. Agha A, Graham DY. Evidence based examination of the African enigma in relation to Helicobacter pylori infection. Scand J Gastroenterol 2005; 40: 523-529.
17. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 suppl 2: 45-51.
18. Howson CP, Hiyama T, Wynder EL. The decline in gastric cancer: epidemiology of an unplanned triumph. Epidemiol Rev 1986; 8: 1-27.
19. Dooley CP, Cohen H, Fitzgibbon PL, et al. Prevalence of Helicobacter pylori infection and histologic hastritis in asymptomatic persons. N Engl J Med 1989; 321: 1562-1566.
20. Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102: 760-766.
21. Youn HS, Ko GH, Chung MH, Lee WK, Cho MJ, Rhee KH. Pathogenesis and prevention of stomach cancer. J Korean Med Sci 1996; 11: 373-385.
22. Feldman RA. Epidemiologic observations and open questions about disease and infection caused by Helicobacter pylori. In Molecular and Cellular Biology, M Aschtman, S. Serbaum (eds), Wymondham, Horizon Scientific 2001, pp. 29-51.
23. Konturek PC, Konturek SJ, Bielañski W, et al. Role of gastrin in gastric cancerogenesis in Helicobacter pylori infected humans. J Physiol Pharmacol 1999; 50: 857-873.
24. Hartwich A, Konturek SJ, Pierzchalski P, et al. Molecular basis of colorectal cancer - role of gastrin and cyclooxygenase-2. Med Sci Monit 2001; 7(6): 1171-1181.
25. Brooks FP, Chey WY, Go VLW, Hansky J, Konturek SJ. Second International Conference on Gastrointestinal Hormones. Am J Dig Dis 1979; 24: 6: 478-481.
26. Konturek SJ. Gastrointestinal hormones and gastric secretion. In: Gastrointestinal Hormones GBJ. Glass (ed.), Raven Press, NY. 1990, 23, pp. 529-564.
27. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiol Biomarkers Prev 1996; 5: 477-481.
28. International Agency for Reseach on Cancer Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes, and Helicobacter pylori. Lyon, International Agency for Research on Cancer 1994; 177-240.
29. Konturek JW. Discovery by Jaworski of Helicobacter pylori and its pathogenic role in peptic ulcer, gastritis and gastric cancer. J Physiol Pharmacol 2003; 54 Suppl 3, 23-41.
30. Rembiasz K, Budzynski A, Karcz D, Konturek P, Konturek SJ, Stachura J. Multifocal atrophic gastritis: pathogenesis and therapeutic implications. Eur J Gastroenterol Hepatol 2005; 17: 857-863.
31. Rembiasz K, Konturek PC, Karcz D, et al. Biomarkers in various types of atrophic gastritis and their diagnostic usefulness. Dig Dis Sci 2005; 50: 474-482.
32. Konturek PCh, Konturek SJ, Starzyńska T, et al. Helicobacter pylori-gastrin link in MALT lymphoma. Aliment Pharmacol Ther 2000; 14: 1311-1318.
33. Konturek PC, Konturek SJ, Pierzchalski P, et al. Gastric malt-lymphoma, gastrin and cyclooxygenases. Acta Gastro-Enterol Belg 2002; 65: 17-23.
34. Sipponen P, Kosunen TU, Valle J, Riihela M, Seppala K. Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol 1992; 45: 319-323.
35. Kokkola A, Valle J, Haapiainen R, Sipponen P, Kivilaakso E, Puokallainen P. Helicobacter pylori infection in young patients with gastric carcinoma. Scand J Gastroenterol 1996; 31: 643-647.
36. Miehlke S, Hackelsberger A, Meining A, et al. Histological diagnosis of helicobacter pylori gastritis in predictive of a high risk of gastric carcinoma. Int J Cancer1997; 73: 837-839.
37. Nomura A, Stemmermann GN, Chyou PH, Kato I, Peres-Perea GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese American in Hawaii. N Engl J Med 1991; 325: 1132-1136.
38. Nomura AM, Stemmermann GN, Chyou PH, Gastric cancer amount the Japanese in Hawaii. Jpn J Cancer Res 1995; 86: 916-923.
39. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2002; 345: 784-789.
40. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterology 2006; 12(3): 354-362.
41. Kuipers EJ, Perez-Perez GI, Meuwissen SG, Blaser MJ. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst 1995; 87: 1777-1780.
42. Chow WH, Blot WJ, Vaughan TL et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998; 90: 150-155.
43. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoa. Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
44. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer. A nested case-control stody. Scand J Gastroenterol 1999; 34: 353-360.
45. Chow WH, Blaser MJ, Blot WJ, et al. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-590.
46. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-280.
47. Bytzer P, Aalykke C, Rune S et al. Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. Scand J Gastroenterol 2000; 35: 1023-1032.
48. McColl KE, Dickson A, El-Nujumi A, El-Omar E, Kelman A. Symptomatic benefit 1-3 years after H pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101-105.
49. Manes G, Mosca S, De Nucci C, Lombardi G, Lioniello M, Balzano A. High prevalence of reflux symptoms in duodenal ulcer patients who develop gastro-oesophageal reflux disease after curing. Helicobacter pylori infection. Dig Liver Dis 2001; 33: 665-670.
50. Konturek SJ, Bielanski W, Gruchala A, et al. Severe atrophic gastritis with extreme hypergastrinemia and gene expression of ornithine decarboxylase (Odc) and cyclo-oxygenase-2 (Cox-2) expression: comparison with gastric cancer. J Clin Gastroenterol 2004; 38: 1, 87-88.
51. Graham DY, Shiotani A. The time to eradicate gastric cancer is now. Gut 2005; 54: 735-738.
52. Wong BC, Zhu GH, Lam SK. Aspirin induced apoptosis in gastric cancer cells. Biomed Pharmacother 1999; 53: 315-318.
53. Sawaoka H, Tsuji S, Tsuji M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-1477.
54. Ristimaki A, Honkamen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-1280.
55. Farrow DC, Vaughan TL, Hansten PD, et al. Use od aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7: 97-102.
56. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer 2001; 84: 965-968.
57. Coogan PF, Rosenberg L, Palmer JR et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9: 119-123.
58. Konturek PC, Konturek SJ, Bielanski W, et al. Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients. Dig Dis Sci 2003; 48: 2005-2017.
59. Wang WH, Huang JQ, Zheng GF, Lam SK, Karlberg J, Wong BC. Non-steroidal antiinflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784-1791.
60. Konturek PC, Bielanski W, Konturek SJ, et al. Progastrin and cyclooxygenase-2 in colorectal cancer. Dig Dis Sci 2002; 47: 9: 1984-1991.
61. Watanabe T, Tada M, Nagai H, Sasaki S, Nakao M. Helicobacter pylori infection induces gastric cancer in Mongoloan gerbils. Gastreonetrology 1998; 115: 642-648.
62. Kodama M, Murakami K, Sato R, Okimoto T, Nizhizono A, Fujioka T. Helicobacter pylori-infected animals model are extremely suitable for the investigation of gastric carcinogenesis. World J Gastroenterol 2005; 11: 7963-7071.
63. Konturek PC, Brzozowski T, Konturek SJ, et al. Functional and morphological aspects of Helicobacter pylori induced gastric cancer in Mongolian gerbils. Eur J Gastroenterol Hepatol 2003; 15: 745-754,
64. Brzozowski T, Konturek PC, Mierzwa M, et al. Effects of probiotics and triple therapy on the cyclooxygernase (COX-2) expression, apoptosis and functional impairment in Helicobacter pylori-infected Mongolian gerbils. Helicobacter 2006; 11: 10-20.